Discovery and Optimization of DNA Gyrase and Topoisomerase IV Inhibitors with Potent Activity against Fluoroquinolone-Resistant Gram-Positive Bacteria
作者:Guillaume Lapointe、Colin K. Skepper、Lauren M. Holder、Duncan Armstrong、Cornelia Bellamacina、Johanne Blais、Dirksen Bussiere、Jianwei Bian、Cody Cepura、Helen Chan、Charles R. Dean、Gianfranco De Pascale、Bhavesh Dhumale、L. Mark Fisher、Mangesh Fulsunder、Bhavin Kantariya、Julie Kim、Sean King、Lauren Kossy、Upendra Kulkarni、Jay Lakshman、Jennifer A. Leeds、Xiaolan Ling、Anatoli Lvov、Sylvia Ma、Swapnil Malekar、David McKenney、Wosenu Mergo、Louis Metzger、Keshav Mhaske、Heinz E. Moser、Mina Mostafavi、Sunil Namballa、Jonas Noeske、Colin Osborne、Ashish Patel、Darshit Patel、Tushar Patel、Philippe Piechon、Valery Polyakov、Krunal Prajapati、Katherine R. Prosen、Folkert Reck、Daryl L. Richie、Mark R. Sanderson、Shailesh Satasia、Bhautik Savani、Jogitha Selvarajah、Vijay Sethuraman、Wei Shu、Kyuto Tashiro、Katherine V. Thompson、Krishniah Vaarla、Lakhan Vala、Dennis A. Veselkov、Jason Vo、Bhavesh Vora、Trixie Wagner、Laura Wedel、Sarah L. Williams、Satya Yendluri、Qin Yue、Aregahegn Yifru、Yong Zhang、Alexey Rivkin
DOI:10.1021/acs.jmedchem.1c00375
日期:2021.5.13
Herein, we describe the discovery and optimization of a novel series that inhibits bacterial DNA gyrase and topoisomerase IV via binding to, and stabilization of, DNA cleavage complexes. Optimization of this series led to the identification of compound 25, which has potent activity against Gram-positive bacteria, a favorable in vitro safety profile, and excellent in vivo pharmacokinetic properties
本文中,我们描述了通过结合和稳定DNA裂解复合物抑制细菌DNA促旋酶和拓扑异构酶IV的新系列的发现和优化。该系列产品的优化导致化合物25的鉴定,该化合物对革兰氏阳性细菌具有强效活性,良好的体外安全性和出色的体内药代动力学特性。在小鼠大腿模型中,发现化合物25对氟喹诺酮敏感的金黄色葡萄球菌感染有效,其剂量低于莫西沙星。肺炎克雷伯菌的拓扑异构酶IV形成的三元复合物的X射线晶体结构,化合物25和切割的DNA表示该化合物不参与水-金属离子桥相互作用,也不与喹诺酮抗性确定区域(QRDR)中的残基形成直接接触。这表明与氟喹诺酮类药物相比,QRDR突变对25种抗菌活性的影响降低的结构基础。